relapsing multiple sclerosis (RMS) – pharmaceutical daily

September 10, 2019 Off

Merck Initiates Pivotal Phase III Programme for Investigational Evobrutinib in Relapsing Multiple Sclerosis

Merck, a leading science and technology company, today announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).

August 28, 2017 Off

No anti-inflammatory effect with GeNeuro’s/Servier’s multiple sclerosis drug at 6 months

By Dino Mustafić

GeNeuro and Servier on Monday said that GNbAC1, for the treatment of certain multiple sclerosis was well tolerated, without statistical…

May 22, 2017 Off

Celgene Corporation reports positive results for its multiple sclerosis drug testing

By Dino Mustafić

Celgene Corporation has announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex).